Benefits and Risks of Inhaled Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease Classified by Blood Eosinophil Counts

Published on Oct 17, 2020in Lung1.817
· DOI :10.1007/S00408-020-00397-4
Zenya Saito5
Estimated H-index: 5
Masahiro Yoshida42
Estimated H-index: 42
+ 3 AuthorsKazuyoshi Kuwano58
Estimated H-index: 58
(Jikei University School of Medicine)
BACKGROUND Chronic obstructive pulmonary disease (COPD) typically includes neutrophilic airway inflammation and eosinophilic inflammation in some cases. Inhaled corticosteroid (ICS) suppresses eosinophilic inflammation of the airway and reduces acute exacerbation (AE). The present study investigated the relationship between ICS and AE in patients with COPD classified by blood eosinophil counts. METHODS Overall, 244 patients with COPD were retrospectively evaluated between 2014 and 2017 and classified into two groups based on blood eosinophil counts (≥ 300/μL and < 300/μL). These patients were then reclassified into subgroups of those with and without ICS. Differences in the characteristics and incidence of AE and pneumonia with AE in each subgroup were evaluated retrospectively. RESULTS All patients with ICS used 320 μg budesonide twice daily. In the group with blood eosinophil counts ≥ 300/μL, patients with ICS had a significantly lower incidence of AE than those without ICS (P = 0.023). Meanwhile, no significant differences were observed in incidence of AE in the group with blood eosinophil counts < 300/μL. In the group with blood eosinophil counts < 300/μL, patients with ICS had a higher incidence of pneumonia with AE (P = 0.009). Conversely, no significant differences were observed in the group with blood eosinophil counts ≥ 300/μL. CONCLUSIONS ICS significantly reduced AE in COPD patients with blood eosinophil counts ≥ 300/μL. Meanwhile, ICS significantly increased pneumonia rate in patients with blood eosinophil count < 300/μL. Blood eosinophil count may be a useful indicator to identify the benefits and risks of ICS in COPD.
📖 Papers frequently viewed together
11 Citations
13 Authors (Umme Kolsum, ..., Dave Singh)
40 Citations
13 Citations
#1Samy Suissa (McGill University)H-Index: 108
#2Sophie Dell'Aniello (McGill University)H-Index: 23
Last. Pierre Ernst (McGill University)H-Index: 76
view all 3 authors...
Background Triple therapy combinations of a long-acting muscarinic antagonist (LAMA), a long-acting beta2-agonist (LABA), and an inhaled corticosteroid (ICS) for COPD were studied in randomized trials and observational studies, with variable results. We compared the effectiveness and safety of triple therapy with a LAMA-LABA combination in a real-world clinical practice setting. Methods We identified a cohort of patients with COPD during 2002 through 2015, ≥ 55 years of age, from the UK's Clinic...
12 CitationsSource
#1Małgorzata Proboszcz (Medical University of Warsaw)H-Index: 5
#2Katarzyna Mycroft (Medical University of Warsaw)H-Index: 1
Last. Rafał Krenke (Medical University of Warsaw)H-Index: 17
view all 8 authors...
AbstractBlood eosinophilia has been proposed as a surrogate marker for airway eosinophilia and as a predictor of treatment response in chronic obstructive pulmonary disease (COPD). The aim of the s...
2 CitationsSource
#1Desiree SchumannH-Index: 4
#2Michael TammH-Index: 76
Last. Daiana StolzH-Index: 33
view all 4 authors...
Background There is controversy regarding the use of blood eosinophil levels as a biomarker of exacerbation risk and responsiveness of patients to inhaled corticosteroids (ICS). Methods Patients in stable COPD with Gold Initiative for Chronic Obstructive Lung Disease airflow obstruction grades II to IV were enrolled in an observational multicenter trial. Concordance was defined as blood eosinophil values persistently lower than or persistently higher than the absolute cutoff points of 150 cells/...
22 CitationsSource
#1Signe Vedel-Krogh (Copenhagen University Hospital)H-Index: 9
#2Børge G. Nordestgaard (UCPH: University of Copenhagen)H-Index: 158
Last. Sune F. Nielsen (Copenhagen University Hospital)H-Index: 22
view all 5 authors...
Blood eosinophil count in chronic obstructive pulmonary disease (COPD) is associated with higher exacerbation rate and favourable response to corticosteroids; however, frequent exacerbations and use of inhaled corticosteroids could elevate pneumonia risk. We tested the hypothesis that high blood eosinophil counts are associated with high risk of pneumonia in individuals with severe COPD from the general population. We included 7180 individuals with COPD from the Copenhagen General Population Stu...
12 CitationsSource
#1Nicolas Roche (Paris V: Paris Descartes University)H-Index: 79
#2Kenneth R. Chapman (UHN: University Health Network)H-Index: 74
Last. Jadwiga A. Wedzicha (NIH: National Institutes of Health)H-Index: 112
view all 10 authors...
Rationale: Post hoc analyses suggest that blood eosinophils have potential as a predictive biomarker of inhaled corticosteroid efficacy in the management of chronic obstructive pulmonary disease (COPD).Objectives: We prospectively investigated the value of blood eosinophils as a predictor of responsiveness to an inhaled corticosteroid/long-acting β2-agonist combination versus a long-acting β2-agonist/long-acting muscarinic antagonist combination for exacerbation prevention.Methods: We conducted ...
104 CitationsSource
#1Claus Vogelmeier (University of Marburg)H-Index: 71
#2Gerard J. Criner (TU: Temple University)H-Index: 83
Last. Alvar Agusti (University of Barcelona)H-Index: 116
view all 22 authors...
This Executive Summary of the Global Strategy for the Diagnosis, Management, and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 report focuses primarily on the revised and novel parts of the document. The most significant changes include: (1) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and...
1,133 CitationsSource
#1Ian D. Pavord (University of Oxford)H-Index: 115
#2Sally LettisH-Index: 11
Last. Neil Barnes (QMUL: Queen Mary University of London)H-Index: 70
view all 4 authors...
Summary Background Inhaled corticosteroids are important in the management of chronic obstructive pulmonary disease (COPD), but can slightly increase the risk of pneumonia in patients with moderate-to-severe COPD. Patients with circulating eosinophil counts of 2% or more of blood leucocytes respond better to inhaled corticosteroids than do those with counts of less than 2% and it was therefore postulated that blood eosinophil count might also have an effect on the risk of pneumonia in patients w...
85 CitationsSource
#1Netsanet A Negewo (University of Newcastle)H-Index: 4
#2Vanessa M. McDonald (University of Newcastle)H-Index: 35
Last. Peter G. Gibson (University of Newcastle)H-Index: 119
view all 7 authors...
Introduction Sputum eosinophilia occurs in approximately one-third of stable chronic obstructive pulmonary disease (COPD) patients and can predict exacerbation risk and response to corticosteroid treatments. Sputum induction, however, requires expertise, may not always be successful, and does not provide point-of-care results. Easily applicable diagnostic markers that can predict sputum eosinophilia in stable COPD patients have the potential to progress COPD management. This study investigated t...
74 CitationsSource
#1Signe Vedel-Krogh (UCPH: University of Copenhagen)H-Index: 9
#2Sune F. Nielsen (UCPH: University of Copenhagen)H-Index: 33
Last. Børge G. Nordestgaard (UCPH: University of Copenhagen)H-Index: 158
view all 5 authors...
Rationale: Whether high blood eosinophils are associated with chronic obstructive pulmonary disease (COPD) exacerbations among individuals with COPD in the general population is largely unknown.Objectives: To test the hypothesis that high blood eosinophils predict COPD exacerbations.Methods: Among 81,668 individuals in the Copenhagen General Population Study, we examined 7,225 with COPD based on spirometry. We recorded blood eosinophils at baseline and future COPD exacerbations longitudinally, d...
195 CitationsSource
15 CitationsSource
Cited By1
#1Peter V. Dicpinigaitis (Albert Einstein College of Medicine)H-Index: 32